Hogan Lovells advises Angelini Pharma as it acquires Catalyst Pharmaceuticals for US$4.1 billion

Following completion of the acquisition, Angelini Pharma intends to integrate the Catalyst portfolio and commercial infrastructure with its own expertise in Brain Health to develop a next-generation therapeutic platform in Rare Diseases. Catalyst's portfolio is expected to significantly strengthen the company's strategic objectives, growing its presence in the United States as part of a balanced strategy that aims to develop the North American market while continuing to strengthen its core business in Europe. Closing is expected in the third quarter of 2026.

The cross-border Hogan Lovells deal team was led by partners Ferigo Foscari (M&A Milan), Peter Cohen-Millstein (M&A, New York), Andrea Pretti (M&A, Milan), Iacopo Canino (Banking, Milan) and Patrizio Messina (Capital Markets, Milan), Matthew Schernecke (Banking & Loan Finance, New York), together with partners Alice Valder Curran and Melissa Bianchi (both Health, Washington, D.C.), Howard Levine (IP, Washington, D.C.), and Jennifer Swan (IP, Silicon Valley), senior associates Beatrice Bertuzzi (Banking and Loan Finance, Milan) and Jake Shaner (M&A, New York), and associates Stefania Maracich (M&A, Milan) and Nic Runnels (M&A, New York).